LUXEMBOURG--(BUSINESS WIRE)--While France has been experiencing a second wave of COVID-19 infections for several weeks now, technicians and clinical pathologists at Eurofins Biomnis have worked round the clock to increase capacity for RT-PCR, the reference test to detect SARS-CoV-2 since March. The laboratory has deployed two very high throughput automated platforms to meet rising testing demand.
In order to analyse the maximum number of samples in the shortest possible time, 1000 m2 of laboratory space, dedicated to SARS-CoV-2 tests, has been established.
The platforms are composed of over one hundred instruments and equipment that manage samples in a process designed to be as automated as possible.
Since March, Eurofins Biomnis' testing capacity has been gradually ramped up to the point where it has now created spare capacity to test 15,000 samples per day in addition to its current volumes. The turnaround time for results is less than 24 hours in 99.8% of cases.
To meet demand, different teams work 24 hours a day, 7 days a week, which makes analyses validation possible even on Saturdays and Sundays. Should the number of tests increase beyond current available capacity, Eurofins Biomnis can collaborate with other laboratories within the Eurofins Group.
To learn more, please visit: https://www.eurofins.com/media-centre/press-releases/2020-10-16_1/ and Eurofins Biomnis
About Eurofins – the global leader in bio-analysis
Eurofins is the global leader in food, environmental, pharmaceutical and cosmetics products testing and in agroscience CRO services. It is also one of the global market leaders in testing and laboratory services for genomics, discovery pharmacology, forensics, advanced material sciences and in esoteric and molecular clinical diagnostic testing.
With over 48,000 staff across a network of more than 800 laboratories in over 50 countries, Eurofins’ companies offer a portfolio of over 200,000 analytical methods.
Eurofins Shares are listed on Euronext Paris Stock Exchange.